Note 3 - Investments

6 Months Ended

Jun. 30, 2022

Notes to Financial Statements

Investment [Text Block]

3. Investments

Available-for-sale securities

The Company’s portfolio of available-for-sale marketable securities consists of the following:

	June 30, 2022
	Amortized		Gross unrealized				Estimated
(In thousands)	Cost		Gains		Losses		Fair Value
Available-for-sale securities, current portion
U.S. government securities	$	10,361	$	-	$	26	$	10,335
Corporate debt securities		11,524		-		8		11,516
Other debt securities		699		-		4		695
Total short-term		22,584		-		38		22,546
Available-for-sale securities, long-term
Other debt securities		491		-		2		489
Total marketable securities	$	23,075	$	-	$	40	$	23,035

There were no outstanding available-for-sale marketable securities as of December 31, 2021.

The contractual maturities of our available-for-sale marketable securities as of June 30, 2022 are as follows:

	Amortized		Estimated
(In thousands)	Cost		Fair Value
Due in one year or less	$	22,584	$	22,546
Due after one year through five years		491		489
Total	$	23,075	$	23,035

Equity investments

We periodically invest in securities of private companies to promote business and strategic objectives. At June 30, 2022 and December 31, 2021, we held non-marketable equity securities without a readily determinable fair value, comprised of $3.4 million in Series A-1 and A-2 Preferred Stock in iVexSol, Inc. and $995,000 in Series E Preferred Stock in PanTHERA CryoSolutions, Inc.